·   Log in

Biocon to launch generic medicines to treat hospital acquired infections

Saturday, August 21, 2010, 13:05 This news item was posted in health category and has 0 Comments so far.

Biocon, India’s leading biotech firm, is planning to launch an array of five affordable drugs to treat hospital acquired infections and other critical illness.

Biocon has created a dedicated division named Comprehensive Care to provide affordable solutions to critical illnesses like nosocomial infections, post surgical complications, trauma and medical emergencies.

Comprehensive Care division will introduce five new products in the initial phase of launch for the treatment of critical illnesses. These products will include platforms based on pneumocandins (a class of echinocandins), ipopeptidies, specialised cephalosporins and carbapenams.

“There is a perceptible increase in hospital acquired infections with respect to critical care illnesses in India. This often requires treatment with specialized anti-infectives. Biocon’s Comprehensive Care division has been set up to counter this growing challenge by providing affordable and specialized solutions to such patients,” stated Kiran Mazumdar Shaw, chairman and managing director, Biocon Ltd.

Comprehensive Care would be the fifth division for Biocon, complementing the existing product portfolios in diabetology, oncology, nephrology and cardiology divisions.

Biocon Ltd reported 52 per cent higher net profit year-on-year at Rs 72.3 crore for the first quarter ended June 2010 against Rs 47.5 crore during the corresponding period last year.

Net sales grew 33 per cent to Rs 322.4 crore (Rs 242.79 crore), buoyed by 37 per cent sales growth in the core business of biopharmaceuticals. They include insulins, immunosuppressants, statins and branded formulations.

Group income grew 33 per cent to Rs 672 crore. Of this, German subsidiary Axicorp contributed Rs 263 crore, or nearly 40 per cent of total revenue.

Biocon is planning to increase its staff strength of 4,750 employees to 5,000 during the next quarter.

Custom research arms Syngene and Clinigene posted higher combined sales of Rs 72 crore.

In the April-June quarter, branded formulations notched a 28 per cent sales growth year on year. They include drugs for diabetes, cancer, renal disorders and cardiology.

Scroll down to comment on this story
You can leave a response, or trackback from your own site.

Leave a Reply